STERIS(US:STE)2020-06-04 14:42Financial Performance - Net sales increased by 3.7% to $236.9 million in 3Q20 compared to $228.6 million in 3Q19[11] - GAAP EPS increased by 85% year-over-year to $0.37 in 3Q20 from $0.20 in 3Q19[12] - Non-GAAP EPS decreased by 70.9% year-over-year to $0.16 in 3Q20 from $0.55 in 3Q19[12] - GAAP Gross profit decreased by 5.5% to $101 million in 3Q20 compared to $106.9 million in 3Q19[20] - Non-GAAP Gross profit decreased by 4.1% to $103 million in 3Q20 compared to $107.4 million in 3Q19[21] - GAAP Income from Operations increased by 51.5% to $22.4 million in 3Q20 compared to $14.8 million in 3Q19[20] - Non-GAAP Income from Operations decreased by 38.6% to $20 million in 3Q20 compared to $32.6 million in 3Q19[21] Segment Performance - Medical sales decreased by approximately 60% in the last five weeks of 3Q20 compared to 2Q20 due to deferred elective procedures[7] - Dental sales decreased by approximately 55% in the last five weeks of 3Q20 compared to 2Q20 due to deferred elective procedures[7] - Life Sciences sales increased by 7.1% to $48.2 million in 3Q20[22] - Dental sales increased by 75.4% to $79.2 million in 3Q20, driven by the acquisition of HuFriedy[24] - Dialysis sales increased by 8.1% to $8.4 million in 3Q20[24] Liquidity and Debt - The company had $115.8 million in cash and cash equivalents as of April 30, 2020[27] - The company's net debt was $861.1 million as of April 30, 2020[33]